Author: readmin
-
Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists
Standard of care for the treatment of neovascular age-related macular degeneration (nAMD) and visual impairment due to centre-involving diabetic macular oedema (DMO) is intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy [1, 2]. Anti-VEGF treatment offers significant visual and anatomic benefits in most patients with nAMD and DMO [1,2,3]. However, frequent anti-VEGF injections are often needed to…
-
-